Increased fluvial runoff terminated inorganic aragonite precipitation on the Northwest Shelf of Australia during the early Holocene.

Inorganic precipitation of aragonite is a common process within tropical carbonate environments. Across the Northwest Shelf of Australia (NWS) such precipitates were abundant in the late Pleistocene, whereas present-day sedimentation is dominated by calcitic bioclasts. This study presents sedimentological and geochemical analyses of core data retrieved from the upper 13 meters of IODP Site U1461 that provide a high-resolution sedimentary record of the last ~15 thousand years. Sediments that formed from 15 to 10.1 ka BP are aragonitic and characterised by small needles (<5 µm) and ooids. XRF elemental proxy data indicate that these sediments developed under arid conditions in which high marine alkalinity favoured carbonate precipitation. A pronounced change of XRF-proxy values around 10.1 ka BP indicates a transition to a more humid climate and elevated fluvial runoff. This climatic change coincides with a shelf-wide cessation of inorganic aragonite production and a switch to carbonate sedimentation dominated by skeletal calcite. High ocean water alkalinity due to an arid climate and low fluvial runoff therefore seems to be a prerequisite for the formation of shallow water aragonite-rich sediments on the NWS. These conditions are not necessarily synchronous to interglacial periods, but are linked to the regional hydrological cycle.

[The willingness to pay for new drugs is based on ethical principles]. / Betalningsviljan för nya läkemedel bygger på etiska principer - NT-rådet tolkar riksdagens plattform för prioritering.

The County Council's board for new therapies (the NT Council) provides recommendations on the use of new drugs based on the ethical platform of priorities, founded by the Swedish parliament. The Council has formulated a policy that interprets the parliamentary ethical platform and operationalize its need and solidarity principle and cost effectiveness principle in four dimensions. The NT Council weighs the health economic evaluation of the drug and the four dimensions: the severity of the condition, the rarity of the condition, the effect size and the data reliability to determine the willingness to pay level and whether the platform allows a recommendation for using of the drug. The severity of the condition has a greater impact than the other dimensions. In the assessment of severity there is also a trade-off between prevention and treatment of manifest diseases and in prevention, the size of the risk of falling ill is of importance. A slightly higher willingness to pay level is reasonable for treatment of very rare conditions, but it is important that identified patients are not given priority over anonymous patient groups with equally strong needs.